The IGF-I signaling pathway

Current Pharmaceutical Design

Volumn 13, Issue 7, 2007, Pages 663-669

  Laviola, Luigi ^a   Natalicchio, Annalisa ^a   Giorgino, Francesco ^a  

^a UNIVERSITY OF BARI   (Italy)

Author keywords

Akt; ERK; IGF I receptor; Insulin receptor; PI 3 kinase

Indexed keywords

INSULIN RECEPTOR SUBSTRATE 1; LIPID; PROTEIN SERINE THREONINE KINASE; PROTEIN SHC; PROTEIN TYROSINE KINASE; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR;

ALPHA CHAIN; APOPTOSIS; AUTOPHOSPHORYLATION; BETA CHAIN; BINDING SITE; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL PROTECTION; CELL TYPE; ENZYME ACTIVATION; ENZYME MECHANISM; ENZYME SUBSTRATE; GENETIC CODE; HORMONE BINDING; HUMAN; INTRACELLULAR SPACE; METABOLIC REGULATION; MITOGENESIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN METABOLISM; PROTEIN STRUCTURE; REVIEW; SIGNAL TRANSDUCTION; TISSUE DIFFERENTIATION;

ANIMALS; BRAIN; HUMANS; INSULIN-LIKE GROWTH FACTOR I; INSULIN-SECRETING CELLS; MUSCLE, SKELETAL; MYOCARDIUM; RECEPTOR, IGF TYPE 1; SIGNAL TRANSDUCTION;

EID: 34047147348     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161207780249146     Document Type: Review

References (116)

1. Florini JR, Ewton DZ, Coolican SA. Growth hormone and the insulin-like growth factor system in myogenesis. Endocr Rev 1996; 17: 481-517.
2. Daughaday WH. A personal history of the origin of the somatomedin hypothesis and recent challenges to its validity. Perspect Biol Med 1989; 32: 194-211.
3. Duan C. Specifying the cellular responses to IGF signals: roles of IGF-binding proteins. J Endocrinol 2002; 175: 41-54.
4. Tollefsen SE, Lajara R, Mc Cusker RH, Clemmons DR, Rotwein P. Insulin-like growth-factors (IGF) in muscle development. Expression of IGF-I receptor, and an IGF binding protein during myoblast differentiation. J Biol Chem 1989; 264: 13810-7.
5. Florini J, Magri K, Ewton D, James P, Grindstaff K, Rotwein P. "Spontaneous" differentiation of skeletal myoblasts is controlled by autocrine secretion of insulin-like growth factor -II. J Biol Chem 1991; 266: 15917-23.
6. Stewart CEH, Rotwein P. Insulin-like growth factor-II is an autocrine survival factor for differentiating myoblasts. J Biol Chem 1996; 271: 11330-8.
7. Ewton DZ, Roof SL, Magri KA, McWade FJ, Florini JR. IGF-II is more active than IGF-I in stimulating L6A1 myogenesis: greater mitogenic actions of IGF-I delay differentiation. J Cell Physiol 1994; 161: 277-84.
8. LeRoith D, Werner H, Beitner-Johnson D, Roberts CT Jr. Molecular and cellular aspects of the insulin-like growth factor I receptor. Endocr Rev 1995; 16: 143-63.
9. Kato H, Faria TN, Stannard B, Roberts Jr CT, LeRoith D. Role of tyrosine kinase activity in signal transduction by the IGF receptor. Characterization of kinase-deficient IGF-I receptors and the action of an IGF-I-mimimetic antibody (α-IR-3). J Biol Chem 1993; 268: 2655-61.
10. Gronborg M, Wulff BS, Rasmussen JS, Kjeldsen T, Gammeltoft S. Structure-function relationship of the insulin-like growth factor-I receptor tyrosine kinase. J Biol Chem 1993; 258: 23435-40.
11. Kato H, Faria TN, Stannard B, Roterts Jr CT, LeRoith D. Essential role of tyrosine residues 1131, 1135, and 1136 of the insulin-like growth factor-I (IGF-I) receptor in IGF-I action. Mol Endocrinol 1994; 8: 40-50.
12. Cheng ZQ, Adi S, Wu NY, Hsiao D, Woo EJ, Filvaroff EH, et al. Functional inactivation of the IGF-I receptor delays differentiation of skeletal muscle cells. J Endocrinol 2000; 167: 175-82.
13. Blakesley VA, Kalebic T, Helman LJ, Stannart B, Faria TN, Roberts Jr CT, et al. Tumorigenic and mitogenic capacities are reduced in transfected fibroblasts expressing mutant IGF-I receptors. The role of tyrosine residues 1250, 1251, and 1316 in the carboxy terminus of the IGF receptor. Endocrinology 1996; 137: 410-7.
14. Siddle K, Urso B, Niesler CA, Cope DL, Molina L, Surinya KH, et al. Specificity in ligand binding and intracellular signalling by insulin and insulin-like growth factor receptors. Biochem Soc Trans 2001; 29: 513-25.
15. Mathews LS, Hammer RE, Behringer RR, D'Ercole AJ, Bell GI, Brinster RL, et al. Growth enhancement of transgenic mice expressing human insulin-like growth factor I. Endocrinology 1988; 123: 2827-33.
16. Liu JP, Baker J, Perkins AS, Robertson EJ, Efstratiadis A. Mice carrying null mutations of the genes encoding insulin-like growth factor I (Igf-1) and type 1 IGF receptor (Igf-r). Cell 1993; 75: 59-72.
17. Accili D, Drago J, Lee EJ, Johnson MD, Cool MH, Salvatore P, et al. Early neonatal death in mice homozygous for a null allele of the insulin receptor gene. Nat Genet 1996; 12: 106-9.
18. Joshi RL. Targeted disruption of the insulin receptor gene in the mouse results in neonatal lethality. EMBO J 1996; 15: 1542-7.
19. Pedrini MT, Giorgino F, Smith RJ. cDNA cloning of the rat IGF I receptors: structural analysis of rat and human IGF I and insulin receptors reveals differences in alternative splicing and receptor-specific domain conservation. Biochem Biophys Res Commun 1994; 202:1038-46.
20. Soos MA, Siddle K. Immunological relationships between receptors for insulin and insulin-like growth factor I. Evidence for structural heterogeneity of insulin-like growth factor I receptors involving hybrids with insulin receptors. Biochem J 1989; 263: 553-63.
21. Moxham CP, Duronio V, Jacobs S. Insulin-like growth factor I receptor beta-subunit heterogeneity. Evidence for hybrid tetramers composed of insulin-like growth factor I and insulin receptor heterodimers. J Biol Chem 1989; 264: 13238-44.
22. Treadway JL, Morrison BD, Goldfine ID, Pessin JE. Assembly of insulin/ insulin-like growth factor-1 hybrid receptors in vitro. J Biol Chem 1989; 264: 21450-3.
23. Bailyes EM, Navé BT, Soos MA, Orr SR, Hayward AC, Siddle K, et al. Insulin receptor/IGF-I receptor hybrids are widely distributed in mammalian tissues: quantification of individual receptor species by selective immunoprecipitation and immunoblotting. Biochem J 1997; 327: 209-15.
24. Soos MA, Field CE, Siddle K. Purified hybrid insulin/insulin-like growth factor-I receptors bind insulin-like growth factor-I, but not insulin, with high affinity. Biochem J 1993; 290: 419-26.
25. Frattali AL, Pessin JE. Relationship between alpha subunit ligand occupancy and beta subunit autophosphorylation in insulin/insulin-like growth factor-1 hybrid receptors. J Biol Chem 1993; 268: 7393-400.
26. Kohanski RA. Insulin receptor autophosphorylation. II. Determination of autophosphorylation sites by chemical sequence analysis and identification of the juxtamembrane sites. Biochemistry 1993; 32: 5773-80.
27. O'Connor R. Identification of domains of the insulin-like growth factor I receptor that are required for protection from apoptosis. Mol Cell Biol 1997; 17: 427-35.
28. Kato H, Faria TN, Stannard B, Roberts Jr CT, LeRoith D. Essential role of tyrosine residues 1131,1135, and 1136 of the insulin-like growth factor-1(IGF-I) receptor in IGF-I action. Mol Endocrinol 1994; 8: 40-50.
29. Myers Jr MG, Sun XJ, Cheatham B, Jachna BR, Glasheen EM, Backer JM, et al. IRS-1 is a common element in insulin and insulin-like growth factor-1 signaling to the phosphatidyl 3′-kinase. Endocrinology 1993; 132: 1421-30.
30. Blakesley VA, Scrimgeour A, Esposito D, Le Roith D. Signaling via the insulin-like growth factor-I receptor: does it differ from insulin receptor signaling? Cytokine Growth Factor Rev 1996; 7:153-9.
31. White MF. The insulin signalling system and the IRS proteins. Diabetologia 1997; 40: S2-17.
32. Rother KI, Imai Y, Caruso M, Beguinot F, Formisano P, Accili D. Evidence that IRS-2 phosphorylation is required for insulin action in hepatocytes. J Biol Chem 1998; 273: 17491-7.
33. Kim JJ, Park BC, Kido Y, Accili D. Mitogenic and metabolic effects of type I IGF receptor overexpression in insulin receptordeficient hepatocytes. Endocrinology 2001; 142: 3354-60.
34. Urso B. Differences in signaling properties of the cytoplasmic domains of the insulin receptor and insulin-like growth factor receptor in 3T3-L1 adipocytes. J Biol Chem 1999; 274: 30864-73.
35. Lammers R, Gray A, Schlessinger J, Ullrich A. Differential signalling potential of insulin- and IGF-1-receptor cytoplasmic domains. EMBO J 1989; 8: 1369-75.
36. Vanhaesebroeck, B, Alessi DR. The PI3K-PDK1 connection: more than just a road to PKB. Biochem J 2000; 346: 561-76.
37. Shepherd PR, Withers DJ, Siddle K. Phosphoinositide 3-kinase: the key switch mechanism in insulin signalling. Biochem J 1998; 333: 471-90.
38. Yamauchi K, Pessin JE. Insulin receptor substrate-1 (IRS-1) and Shc compete for a limited pool of Grb2 in mediating insulin downstream signaling. J Biol Chem 1994; 269: 31107-14.
39. Pelicci G, Lanfrancone L, Grignani F, McGlade J, Cavallo F, Forni G, et al. A novel transforming protein (SHC) with an SH2 domain is implicated in mitogenic signal transduction. Cell 1992; 70: 93-104.
40. Migliaccio E, Mele S, Salcini AE, Pelicci G, Lai KM, Superti-Furga G, et al. Opposite effects of the p52shc/p46shc and p66shc splicing isoforms on the EGF receptor-MAP kinase-fos signalling pathway. EMBO J 1997; 16: 706-16
41. Ventura A, Luzi L, Pacini S, Baldari CT, Pelicci PG. The p66Shc longevity gene is silenced through epigenetic modifications of an alternative promoter. J Biol Chem 2002; 277: 22370-6.
42. Migliaccio E, Giorgio M, Mele S, Pelicci G, Reboldi P, Pandolfi PP, et al. The p66shc adaptor protein controls oxidative stress response and life span in mammals. Nature 1999; 402: 309-13.
43. Nemoto S, Finkel T. Redox regulation of forkhead proteins through a p66shc-dependent signaling pathway. Science 2002; 295: 2450-2.
44. Natalicchio A, Laviola L, De Tullio C, Renna LA, Montrone C, Perrini S, et al. Role of the p66Shc isoform in insulin-like growth factor I receptor signaling through MEK/Erk and regulation of actin cytoskeleton in rat myoblasts. J Biol Chem 2004; 279(42): 43900-9.
45. Davol PA, Bagdasaryan R, Elfenbein GJ, Maizel AL, Frackelton AR Jr. Shc proteins are strong, independent prognostic markers for both node-negative and node-positive primary breast cancer. Cancer Res 2003; 63: 6772-83.
46. Derijard B, Hibi M, Wu I, Barret T, Su B, Deng T, et al. JNK1: a protein kinase stimulated by UV light and ha-Ras that binds and phosphorylates the C-Jun activation domain. Cell 1994; 76: 1025-37.
47. Han J, Lee J-D, Bibbs L, Ulevitch RJ. A MAP kinase targeted by endotoxin and hyperosmolarity in mammalian cells. Science 1994; 265: 808-11.
48. Rouse J, Cohen P, Trigon S, Morange M, Alonso-Liamazares A, Zamanillo D, et al. A novel kinase cascade triggered by stress and heat shock that stimulates MAP kinase-2 and phosphorylation of the small heat shock proteins. Cell 1994; 78: 1027-37.
49. Davis RJ. The mitogen-activated protein kinase signal transduction pathway. J Biol Chem 1993; 268: 14553-6.
50. Zimmermann S, Moelling K. Phosphorylation and regulation of raf by akt (protein kinase B). Science 1999; 286: 1741-4.
51. Rommel C, Clarke BA, Zimmermann S, Nunez L, Rossman R, Reid K, et al. Differentiation stage-specific inhibition of the raf-MEK-ERK pathway by Akt. Science 1999; 286: 1738-41.
52. Beitner-Johnson D, Le Roith D. Insulin-like growth factor-I stimulates tyrosine phosphorylation of endogenous c-Crk. J Biol Chem 1995; 270: 5187-90.
53. Matsuda M, Hashimoto Y, Muroya K, Hasegawa H, Kurata T, Tanaka S. CRK protein binds to two guanine nucleotide-releasing proteins for the Ras family and modulates nerve growth factorinduced activation of Ras in PC12 cells. Mol Cell Biol 1994; 14: 5495-500.
54. Okada S, Pessin JE. Insulin and epidermal growth factor stimulate a conformational change in Rap1 and dissociation of the CrkIIC3G complex.. J Biol Chem 1997; 272: 28179-82.
55. Okada S, Matsuda M, Anafi M, Pawson T, Pessin JE. Insulin regulates the dynamic balance between Ras and Rap1 signaling by coordinating the assembly states of the Grb2-SOS and CrkII-C3G complexes. EMBO J 1998; 17: 2554-65.
56. Beitner-Johnson D, Blakesley VA, Shen-Orr Z, Jiemnez M, Stannard B, Wang L-M. The protooncogene product c-Crk associates with insulin receptor substrate-1 and 4Ps. Modulation by insulin-like growth factor-I (IGF) and enhanced IGF-I signaling. J Biol Chem 1996; 271: 9287-90.
57. Sugimoto S, Wandless TJ, Shoelson SE, Neel BG, Walsh CT. Activation of the SH2-containing protein tyrosine phosphatase, SHPTP2, by phosphotyrosine-containing peptides derived from insulin receptor substrate-1. J Biol Chem 1994; 269: 13614-22.
58. Buckley DA, Cheng A, Kiely PA, Tremblay ML, O'Connor R. Regulation of insulin-like growth factor type I (IGF-I) receptor kinase activity by protein tyrosine phosphatase 1B (PTP-1B) and enhanced IGF-I-mediated suppression of apoptosis and motility in PTP-1B-deficient fibroblasts. Mol Cell Biol 2002; 22: 1998-2010.
59. LeRoith D, Werner H, Beitner-Johnson D, Roberts CT Jr. Molecular and cellular aspects of the insulin-like growth factor I receptor. Endocr Rev 1995; 16: 143-63.
60. Hansen H, Svensson U, Zhu J, Laviola L, Giorgino F, Wolf G, et al. Interaction between the Grb10 SH2 domain and the insulin receptor carboxyl terminus. J Biol Chem 1996; 271: 8882-6.
61. Dey BR, Frick K, Lopaczynski W, Nissley SP, Furlanetto RW. Evidence for the direct interaction of the insulin-like growth factor I receptor with IRS-1, Shc, and Grb10. Mol Endocrinol 1996; 10: 631-41.
62. Laviola L, Giorgino F, Chow JC, Baquero JA, Hansen H, Ooi J, et al. The adapter protein Grb10 associates preferentially with the insulin receptor as compared with the IGF-I receptor in mouse fibroblasts. J Clin Invest 1997; 99: 830-7.
63. He W, Rose DW, Olefsky JM, Gustafson TA. Grb10 interacts differentially with the insulin receptor, insulin-like growth factor I receptor, and epidermal growth factor receptor via the Grb10 Src homology 2 (SH2) domain and a second novel domain located between the pleckstrin homology and SH2 domains. J Biol Chem 1998; 273: 6860-7.
64. Liu F, Roth RA. Grb-IR: a SH2-domain-containing protein that binds to the insulin receptor and inhibits its function. Proc Natl Acad Sci USA 1995; 92: 10287-91.
65. Morrione A, Valentinis B, Resnicoff M, Xu S, Baserga R. The role of mGrb10alpha in insulin-like growth factor I-mediated growth. J Biol Chem 1997; 272: 26382-7.
66. Stein EG, Gustafson TA, Hubbard SR. The BPS domain of Grb10 inhibits the catalytic activity of the insulin and IGF1 receptors. FEBS Lett 2001; 493: 106-111.
67. Mounier C, Lavoie L, Dumas V, Mohammad-Ali K, Nantel A, Bergeron JJ, et al. Specific inhibition by hGRB10zeta of insulin-induced glycogen synthase activation: evidence for a novel signaling pathway. Mol Cell Endocrinol 2001; 173: 15-27.
68. O'Neill TJ, Rose DW, Pillay TS, Hotta K, Olefsky JM, Gustafson TA. Interaction of a GRB-IR splice variant (a human GRB10 homolog) with the insulin and insulin-like growth factor I receptors. Evidence for a role in mitogenic signaling. J Biol Chem 1996; 271: 22506-13.
69. Wang J, Dai H, Yousaf N, Moussaif M, Deng Y, Boufelliga A. Grb10, a positive, stimulatory signaling adapter in platelet-derived growth factor BB-, insulin-like growth factor I-, and insulin-mediated mitogenesis. Mol Cell Biol 1999; 19: 6217-28.
70. Yoshihashi H, Maeyama K, Kosaki R, Ogata T, Tsukahara M, Goto Y, et al. Imprinting of human GRB10 and its mutations in two patients with Russell-Silver syndrome. Am J Hum Genet 2000; 67: 476-82.
71. Craparo A, Freund R, Gustafson TA. 14-3-3 (epsilon) interacts with the insulin-like growth factor I receptor and insulin receptor substrate I in a phosphoserine-dependent manner. J Biol Chem 1997; 272: 11663-9.
72. Furlanetto RW, Dey BR, Lopaczynski W, Nissley SP. 14-3-3 proteins interact with the insulin-like growth factor receptor but not the insulin receptor. Biochem J 1997; 327: 765-71.
73. Baldin V. 14-3-3 proteins and growth control. Prog Cell Cycle Res 2000; 4:49-60.
74. Imamura T, Vollenweider P, Egawa K, Clodi M, Ishibashi K, Nakashima N, et al. G alpha-q/11 protein plays a key role in insulin-induced glucose transport in 3T3-L1 adipocytes. Mol Cell Biol 1999; 19: 6765-74.
75. Hallak H, Seiler AEM, Green JS, Ross BN, Rubin R. Association of heterotrimeric G(i) with the insulin-like growth factor-I receptor. Release of G (betagamma) subunits upon receptor activation. J Biol Chem 2000; 275: 2255-8.
76. Dalle S, Ricketts W, Imamura T, Vollenweider P, Olefsky JM. Insulin and insulin-like growth factor I receptors utilize different G protein signaling components. J Biol Chem 2001; 276: 15688-95.
77. Quinn LS, Ehsan M, Steinmetz B, Kaleko M. Ligand-dependent inhibition of myoblast differentiation by overexpression of the type-1 insulin-like growth factor receptor. J Cell Physiol 1993; 156: 453-61.
78. Quinn LS, Steinmetz B, Maas A, Ong L, Kaleko M. Type-1 insulin-like growth factor receptor overexpression produces dual effects on myoblast proliferation and differentiation. J Cell Physiol 1994; 159: 387-98.
79. Coolican SA, Samuel DS, Ewton DZ, McWade FJ, Florini JR. The mitogenic and myogenic actions of insulin-like growth factors utilize distinct signaling pathways. J Biol Chem 1997; 272: 6653-62.
80. Thomas G, Hall MN. TOR signaling and control of cell growth. Curr Opin Cell Biol 1997; 9: 782-7.
81. Chakravarthy MV, Abraha TW, Schwartz RJ, Fiorotto ML, Booth FW. Insulin-like growth factor-I extends in vitro replicative life span of skeletal muscle satellite cells by enhancing G1/S cell cycle progression via the activation of phosphatidylinositol 3′-kinase/Akt signaling pathway. J Biol Chem 2000; 275: 35942-52.
82. Mehrhof FB, Muller FU, Bergmann MW, Li P, Wang Y, Schmitz W, et al. In cardiomyocyte hypoxia, insulin-like growth factor-Iinduced antiapoptotic signaling requires phosphatidylinositol-3- OH-kinase-dependent and mitogen-activated protein kinasedependent activation of the transcription factor cAMP response element-binding. Circulation 2001; 104: 2088-94.
83. Yu CF, Roshan B, Liu ZX, Cantley LG. ERK regulates the hepatocyte growth factor-mediated interaction of Gab1 and the phosphatidylinositol 3-kinase. J Biol Chem 2001; 276: 32252-8.
84. Sarbassov DD, Peterson CA. Insulin receptor substrate-1 and phosphatidylinositol 3-kinase regulate extracellular signal-regulated kinase-dependent and -independent signaling pathways during myogenic differentiation. Mol Endocrinol 1998; 12: 1870-8.
85. Giorgino F, Smith RJ. Dexamethasone enhances insulin-like growth factor-1 effects on skeletal muscle cell proliferation. Role of specific intracellular signalling pathways. J Clin Invest 1995; 96: 1473-83.
86. Wang PH. Roads to survival: insulin-like growth factor-1 signaling pathways in cardiac muscle. Circ Res 2001; 88: 552-4.
87. Li B, Setoguchi M, Wang X, Andreoli AM, Leri A, Malhotra A et al. Insulin-like growth factor-1 attenuates the detrimental impact of nonocclusive coronary artery constriction on the heart. Circ Res 1999; 84: 1007-19.
88. Buerke M, Murohara T, Skurk C, Nuss C, Tomaselli K, Lefer AM. Cardioprotective effect of insulin-like growth factor I in myocardial ischemia followed by reperfusion. Proc Natl Acad Sci USA 1995; 92: 8031-5.
89. Wang L, Ma W, Markovich R, Chen JW, Wang PH. Regulation of cardiomyocyte apoptotic signaling by insulin-like growth factor I. Circ Res 1998; 83: 516-22.
90. Ren J, Samson WK, Sowers JR. Insulin-like growth factor I as a cardiac hormone: physiological and pathophysiological implications in heart disease. J Mol Cell Cardiol 1999; 31: 2049-61.
91. Wu W, Lee WL, Wu YY, Chen D, Liu TJ, Jang A, et al. Expression of constitutively active phosphatidylinositol 3-kinase inhibits activation of caspase 3 and apoptosis of cardiac muscle cells. J Biol Chem 2000; 275: 40113-9.
92. Liu T, Lai H, Wu W, Chinn S, Wang PH. Developing a strategy to define the effects of insulin-like growth factor-1 on gene expression profile in cardiomyocytes. Circ Res 2001; 88: 1231-8.
93. Foncea R, Andersson M, Ketterman A, Blakesley V, Sapag-Hagar M, Sugden PH, et al. Insulin-like growth factor-I rapidly activates multiple signal transduction pathways in cultured rat cardiac myocytes. J Biol Chem 1997; 272: 19115-24.
94. Fujio Y, Nguyen T, Wencker D, Kitsis RN, Walsh K. Akt promotes survival of cardiomyocytes in vitro and protects against ischemia-reperfusion injury in mouse heart. Circulation 2000; 101: 660-7.
95. Cheng CM, Reinhardt RR, Lee WH, Joncas G, Patel SC, Bondy CA. Insulin-like growth factor 1 regulates developing brain glucose metabolism. Proc Natl Acad Sci USA 2000; 97: 10236-41.
96. Cheng CM, Tseng V, Wang J, Wang D, Matyakhina L, Bondy CA. Tau is hyperphosphorylated in the insulin-like growth factor-I null brain. Endocrinology 2005; 146: 5086-91.
97. Crowder RJ, Freeman R S. Glycogen synthase kinase-3 beta activity is critical for neuronal death caused by inhibiting phosphatidylinositol 3-kinase or Akt but not for death caused by nerve growth factor withdrawal. J Biol Chem 2000; 275: 34266-71.
98. Hetman M, Cavanaugh JE, Kimelman D, Xia Z. Role of glycogen synthase kinase-3beta in neuronal apoptosis induced by trophic withdrawal. J Neurosci 2000; 20: 2567-74.
99. Li M, Wang X, Meintzer MK, Laessig T, Birnbaum MJ, Heidenreich KA. Cyclic AMP promotes neuronal survival by phosphorylation of glycogen synthase kinase 3beta. Mol Cell Biol 2000; 20: 9356-63.
100. Tong N, Sanchez JF, Maggirwar SB, Ramirez SH, Guo H, Dewhurst S, et al. Activation of glycogen synthase kinase 3 beta (GSK-3beta) by platelet activating factor mediates migration and cell death in cerebellar granule neurons. Eur J Neurosci 2001; 13: 1913-22.
101. Verspohl EJ, Ammon HPT. Evidence for presence of insulin receptors in rat islets of Langerhans. J Clin Invest 1980; 65: 1230-7.
102. Van Schravendijk CF, Foriers A, Van Den Brande JL, Pipeleers D. Evidence for the presence of type I insulin-like growth factor receptors on rat pancreatic A and B cells. Endocrinology 1987; 121: 1784-8.
103. Kulkarni RN, Bruning JC, Winnay JN, Postic C, Magnuson MA, Kahn CR. Tissue-specific knockout of the insulin receptor in pancreatic beta cells creates an insulin secretory defect similar to that in type 2 diabetes. Cell 1999; 96: 329-39.
104. Kulkarni RN, Winnay JN, Daniels M, Bruning JC, Flier SN, Hanahan D, et al. Altered function of insulin receptor substrate-1-deficient mouse islets and cultured beta-cell lines. J Clin Invest 1999; 104: R69-75.
105. Kubota N, Tobe K, Terauchi Y, Eto K, Yamauchi T, Suzuki R, et al. Disruption of insulin receptor substrate 2 causes type 2 diabetes because of liver insulin resistance and lack of compensatory beta-cell hyperplasia. Diabetes 2000; 49: 1880-9.
106. Tuttle RL, Gill NS, Pugh W, Lee JP, Koeberlien B, Furth EE, et al. Regulation of pancreatic beta-cell growth and survival by the serine/ threonine protein kinase Akt1/PKBalpha. Nat Med 2001; 7: 1133-7.
107. Xuan S, Kitamura T, Nakae J, Politi K, Kido Y, Fisher PE, et al. Defective insulin secretion in pancreatic beta cells lacking type 1 IGF receptor. J Clin Invest 2002; 110: 1011-9.
108. Porksen N, Hussain MA, Bianda TL, Nyholm B, Christiansen JS, Butler PC, et al. IGF-I inhibits burst mass of pulsatile insulin secretion at supraphysiological and low IGF-I infusion rates. Am J Physiol 1997; 272: E352-8.
109. Leahy JL, Vandekerkhove KM. Insulin-like growth factor-I at physiological concentrations is a potent inhibitor of insulin secretion. Endocrinology 1990; 126: 1593-8.
110. Czech M. Structural and functional homologies in the receptors for insulin and the insulin-like growth factors. Cell 1982; 31: 8-10.
111. Bonner-Weir S. Regulation of pancreatic beta cell mass in vivo. Recent Prog Horm Res 1994; 49: 91-104.
112. Kulkarni RN, Kahn CR. In: Habener JF, Hussain M Eds, Molecular Basis of Pancreas Development and Function. New York, Kluwer 2001; 299-323.
113. Smith FE, Rosen KM, Villa KL, Weir GC, Bonner-Weir S. Enhanced insulin-like growth factor I gene expression in regenerating rat pancreas. Proc Natl Acad Sci USA 1991; 88: 6152-6.
114. Giles GI. The redox regulation of thiol dependent signaling pathways in cancer. Curr Pharm Des 2006; 12(34): 4427-43.
115. Tas SW, Remans PH, Reedquist KA, Tak PP. Signal transduction pathways and transcription factors as therapeutic targets in inflammatory disease: towards innovative antirheumatic therapy. Curr Pharm Des 2005; 11(5): 581-611.
116. Werry TD, Christopoulos A, Sexton P M. Mechanisms of ERK1/2 regulation by seven-transmembrane-domain receptors. Curr Pharm Des 2006; 12(14): 1683-702.